Teva Pharmaceutical Industries Management
Management criteria checks 2/4
Teva Pharmaceutical Industries' CEO is Richard Francis, appointed in Jan 2023, has a tenure of 1.25 years. total yearly compensation is $25.71M, comprised of 6.2% salary and 93.8% bonuses, including company stock and options. directly owns 0.011% of the company’s shares, worth $1.60M. The average tenure of the management team and the board of directors is 2.5 years and 6.8 years respectively.
Key information
Richard Francis
Chief executive officer
US$25.7m
Total compensation
| CEO salary percentage | 6.2% |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.01% |
| Management average tenure | 2.5yrs |
| Board average tenure | 6.8yrs |
Recent management updates
Recent updates
Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet
Mar 26
Teva Pharmaceutical Industries: Potential Outweighs Concerns
Mar 25Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities
Feb 26A Review Of Teva's Prospects
Feb 15Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Business And Shares Still Trailing The Industry
Jan 07These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt In A Risky Way
Dec 11Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)
Dec 08Teva: Deeply Undervalued FCF Machine
Nov 20Teva: Focus On Innovation And Growth Means The Times They Are A Changing
Sep 14Teva Pharmaceutical Industries (NYSE:TEVA) Has No Shortage Of Debt
Sep 09The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider
Aug 26Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain
Aug 02Teva Pharmaceutical: Lacking Capabilities For Strategic Investments
Jul 20Teva Pharmaceutical: New Growth Plan Could Restore Investor Confidence
Jun 15Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Is Weighed Down By Its Debt Load
Jun 06Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Feb 20What To Expect From Teva Pharmaceutical In 2023 With A New CEO
Feb 15Can Teva Pharmaceutical's Q4 results bring positive surprise?
Feb 07Teva Pharmaceutical: Stuck In A Cycle Of Hope And Disappointment
Jan 19Tamiflu supplies released from national stockpile as nationwide shortage persists
Jan 12Teva Pharmaceutical: 2023 Could Finally Be The Stock's Breakout Year
Dec 28Federal appeals court temporarily blocks generics of Vanda's Hetlioz by Teva, Apotex
Dec 16Boston jury orders Lilly to pay $176.5M to Teva in migraine drug patent suit
Nov 10Teva Pharmaceutical to pay New York $523M as part of opioid settlement
Nov 03Teva data indicates long-term benefit of Austedo for chorea associated with Huntington's
Oct 18Novartis division Sandoz reports supply issue of generic ADHD drug Adderall - Bloomberg
Oct 06Teva Pharmaceutical: Slow And Steady Road To A Higher Share Price
Sep 28Teva Pharmaceutical: Past Behind And A Promising 2023
Sep 16Teva wins European approval for biosimilar to Roche’s eye therapy Lucentis
Aug 29These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt Extensively
Aug 05Teva flags supply constraints to ADHD drug Adderall as demand rises - Bloomberg
Aug 03Forex volatility, performance of generic drugs, opioid settlements in focus for Teva's Q2 earnings
Jul 26Teva again in the sights of New York Attorney General over alleged role in opioid crisis
Jul 11Teva names new medical chief
Jul 01Teva Pharma Trends Lower Ahead Of A Key Shareholder Meeting This Week
Jun 203 Reasons To Buy Teva At $10
Apr 07Does Teva Pharmaceutical Industries (NYSE:TEVA) Have A Healthy Balance Sheet?
Mar 24Teva Pharmaceutical: Prepare For Takeoff
Feb 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$26m | US$2m | -US$559m |
Compensation vs Market: Richard's total compensation ($USD25.71M) is above average for companies of similar size in the US market ($USD13.52M).
Compensation vs Earnings: Insufficient data to compare Richard's compensation with company performance.
CEO
Richard Francis (55 yo)
1.3yrs
Tenure
US$25,706,880
Compensation
Mr. Richard D. Francis serves as President and Chief Executive Officer at Teva Pharmaceutical Industries Limited since January 01, 2022 and serves as its Director. Mr. Francis served as Division Head and C...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.3yrs | US$25.71m | 0.011% $ 1.6m | |
| Executive VP & CFO | 4.3yrs | US$4.94m | 0.064% $ 9.4m | |
| Executive Vice President of Global Operations | 4.5yrs | US$4.25m | 0.035% $ 5.2m | |
| Executive Vice President of International Markets Commercial | 2.7yrs | US$3.73m | 0.028% $ 4.1m | |
| Executive Vice President of European Commercial | 6.4yrs | US$5.16m | 0.0087% $ 1.3m | |
| Senior VP & Chief Accounting Officer | 2.4yrs | no data | 0.0029% $ 433.2k | |
| Head of Investor Relations | no data | no data | no data | |
| Senior Vice President | 1.8yrs | no data | no data | |
| Executive VP & Chief Legal Officer | less than a year | no data | no data | |
| Acting Head of Global Human Resources | less than a year | no data | 0.0013% $ 197.5k | |
| Senior Vice President of Investor Relations | no data | no data | no data | |
| Senior VP & Chief Internal Auditor | 9.9yrs | no data | no data |
2.5yrs
Average Tenure
53.5yo
Average Age
Experienced Management: TEVA's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | no data | US$25.71m | 0.011% $ 1.6m | |
| Independent Chairman of the Board | 9.3yrs | US$539.99k | 0.033% $ 4.8m | |
| Independent Director | 15.3yrs | US$340.00k | 0.18% $ 27.0m | |
| Independent Director | 8.6yrs | US$355.00k | 0.0075% $ 1.1m | |
| Independent Director | 6.8yrs | US$340.00k | 0.0066% $ 969.6k | |
| Independent Director | 8.6yrs | US$330.00k | 0.0073% $ 1.1m | |
| Independent Director | 3.8yrs | US$325.46k | 0.0038% $ 558.5k | |
| Independent Director | 2.5yrs | US$330.00k | 0.0025% $ 364.0k | |
| Independent Director | 6.8yrs | US$320.00k | 0.0066% $ 969.6k | |
| Independent Director | 5.8yrs | US$315.25k | 0.0059% $ 873.8k | |
| Independent Director | less than a year | US$176.66k | no data |
6.8yrs
Average Tenure
63yo
Average Age
Experienced Board: TEVA's board of directors are considered experienced (6.8 years average tenure).